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Abstract Classical galactosemia (CG) is an inborn error of
galactose metabolism. Evidence-based guidelines for the
treatment and follow-up of CG are currently lacking, and
treatment and follow-up have been demonstrated to vary
worldwide. To provide patients around the world the same
state-of-the-art in care, members of The Galactosemia
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Network (GalNet) developed an evidence-based and inter-
nationally applicable guideline for the diagnosis, treat-
ment, and follow-up of CG. The guideline was developed
using the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) system. A sys-
tematic review of the literature was performed, after key
questions were formulated during an initial GalNet meet-
ing. The first author and one of the working group experts
conducted data-extraction. All experts were involved in
data-extraction. Quality of the body of evidence was eval-
uated and recommendations were formulated. Whenever
possible recommendations were evidence-based, if not
they were based on expert opinion. Consensus was reached
by multiple conference calls, consensus rounds via e-mail
and a final consensus meeting. Recommendations address-
ing diagnosis, dietary treatment, biochemical monitoring,
and follow-up of clinical complications were formulated.
For all recommendations but one, full consensus was
reached. A 93 % consensus was reached on the recommen-
dation addressing age at start of bone density screening.
During the development of this guideline, gaps of knowl-
edge were identified in most fields of interest, foremost in




Clinicians should confirm the diagnosis of CG by the mea-
surement of GALT enzyme activity in red blood cells (absent
or significantly decreased), and/or GALT gene analysis. It is
enough to confirm the diagnosis by genetic analysis only, if
the detected variations are reported as disease causing in ge-
netic variation databases (Calderon et al. 2007; http://www.
arup.utah.edu/database/galt/galt_welcome.php) and the
biological parents each carry one variation.
Recommendation #2 (expert opinion, +)
Clinicians should treat patients with a red blood cell GALT
enzyme activity below 10 % and/or pathologic variations on
both alleles of the GALT gene, including p.S135L, with a
galactose-restricted diet. There is not enough evidence to con-
clude whether patients with 10–15 % red blood cell residual
GALT activity should or should not be treated.
Recommendation #3 (expert opinion, +)
We recommend not to treat patients with the Duarte variant.
Dietary management
Recommendation #4 (++)
Clinicians should immediately commence a galactose-re-
stricted diet (e.g., soy-based, casein hydrolysate or elemental
formula) if classical galactosemia is suspected in an infant,
without waiting for confirmation of the diagnosis.
Recommendation #5 (expert opinion, +)
We recommend treating patients with CG with a life-long
galactose-restricted diet that only eliminates sources of lactose
and galactose from dairy products, but permits galactose from
non-milk sources that contribute minimal dietary galactose.
Within this definition we accept that small amounts of galac-
tose are present in specific mature cheeses and caseinates. At
present there is insufficient evidence to support a specific age-
related recommendation for the quantity of galactose allowed
in the diet.
Recommendation #6 (+)
We recommend allowing any amount and type of fruits,
vegetables, legumes, unfermented soy-based products, mature
cheeses (with galactose content <25 mg/100 g), and the food
additives sodium or calcium caseinate, in the diet for classical
galactosemia. Although higher in galactose, all fermented
soy-based products can be allowed in the small quantities that
are typically used in the diet.
Recommendation #7 (+)
We recommend an annual dietary assessment of calcium
and vitamin D intake with measurement of plasma total 25-
OH-vitamin D levels. Both calcium and vitamin D should be
supplemented as necessary following the age-specific recom-
mendations for the general population.
Biochemical follow-up
Recommendation #8 (++)
In the first year of life clinicians should measure red blood
cell Gal-1-P levels at diagnosis, and after 3 and 9 months of
dietary galactose restriction.
Recommendation #9 (expert opinion, +)
We recommend measuring red blood cell Gal-1-P levels
yearly after the first year of life until an individual baseline
has been established.
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Recommendation #10 (expert opinion, +)
We recommend measuring red blood cell Gal-1-P levels in
case of increase in galactose intake and concern about intox-
ication.
Recommendation #11 (expert opinion, +)





Clinicians should refer patients for testing of devel-
opmental quotient (DQ) and intellectual quotient (IQ),
to obtain a well-validated measure of development and
cognitive abilities. At minimum, testing should be done
at:
Age 2–3 years: to assess early speech/language and
motor development in time for early intervention, using
a standardized test instrument such as the Bayley Scales
of Infant and Toddler Development (BSID) or a similar
measure.
Age 4–5 years: to assess school readiness and need for
occupational therapy and speech-language therapy, using a
standardized test instrument such as the Wechsler Preschool
and Primary Scale of Intelligence (WPPSI) or a similar
measure.
Age 8–10 years: to assess cognitive development, specific
areas of strengths and weaknesses and the need for special
therapies, using a standardized test instrument such as the
Wechsler Intelligence Scale for Children (WISC) or a similar
measure.
Age 12–14 years: to assess cognitive development and
specific areas of strengths and weaknesses and to assess the
need for special therapies, using a standardized test instrument
such as the Wechsler Intelligence Scale for Children (WISC)
or a similar measure.
Age 15 years and older: according to needs, specific
questions.
(consider combining these assessments with speech and
language screening, recommendation #15, and psychosocial
development screening, recommendation #21)
Recommendation #13 (expert opinion, +)
For obtaining a measure of functioning when formalized
testing is not possible or when additional assessments are
needed between formalized testing points, we recommend
using a validated parent/informant questionnaire, such as the
Adaptive Behavior Assessment System (ABAS) or a similar
measure.
Recommendation #14 (expert opinion, +)
We recommend a clinical assessment of executive function,
if feasible in the clinic, with specific attention to processing
speed and visual spatial comprehension. In children (8–
10 years) as a first screening use the Behavior Rating
Inventory of Executive Function (BRIEF), and in adolescents
(12–14 years) and in young adults (18–20 years) use the
Cambridge
Neuropsychological Test Automated Battery (CANTAB),
the Amsterdam Neuropsychological Tasks program (ANT) or
a similar measure, with follow-up, as needed.
Speech and language
Recommendation #15 (++)
All children with CG should be screened for speech and
language delay at ages 7–12 months, 2 years, 3 years, and
5 years (consider combining with screening for cognitive dis-
orders, recommendation #12). If children show low or border-
line speech and language development, full assessments
should be conducted.
Recommendation #16 (expert opinion, +)
We recommend that an assessment of speech and language
includes hearing screening, a brief assessment of pre-linguistic
communication (<2 years of age) and expressive, receptive,
and pragmatic language use, structure-function examination,
motor speech (observation of respiration, resonance, voice,
articulation), and speech intelligibility for all children not
meeting age appropriate milestones. We recommend a cogni-
tive evaluation, as well if, a disorder is suspected.
Recommendation #17 (expert opinion, +)
For children who are not meeting age appropriate
speech or language milestones, we recommend treatment
based on guidelines for treatment of speech, language, and
voice disorders in the general population. Therapy should
begin during the first year of life and include modeling
and training of gestural communication to increase infant
and toddler language development. Play-based milieu for
language development is recommended during the second
year of life. Individual speech therapy focused on high
repetition of a small number of targets should begin dur-
ing the second year of life and continue as needed
throughout the preschool and elementary school years.




Clinicians should screen patients with CG for neurological
involvement by clinical examination from the age of
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2–3 years. Such screening should include examination for
ataxia, tremor, dysmetria, and dystonia. If a specific neurolog-
ical deficit is noted, monitoring of progression with a desig-
nated scale is advised. It is suggested to screen adult patients
annually and to record progression, if any. Pediatric patients
could be screened more frequently (every 6 months) in order
to identify potentially modifiable neurological problems.
Recommendation #19 (+)
We recommend asking patients or caregivers about onset of
seizure and seizure-like activity since previous examination
and perform an EEG, if indicated.
Recommendation #20 (expert opinion, +)
We do not recommend routine brain and spinal cord imag-
ing in the follow-up of patients with CG.
In those patients with significant or progressive neurolog-
ical symptoms and signs, imaging may be warranted to (1)
determine if a second condition is present or (2) further define
the development and progression of neuroradiology findings
in individual patients.
Psychosocial development
Recommendation #21 (expert opinion, +)
We recommend screening children for psychosocial defi-
cits, including autism spectrum disorders, sensory integration
problems, depression and anxiety, using standardized ques-
tionnaires such as the Behavior Assessment System for
Children, Second Edition (BASC-2) in English or a similar
tool in other language. We recommend performing this
screening at age 2 years in combination with screening for
speech and language delays (see recommendation #15) and
to combine this screening with developmental testing at ages
4–5 years, 8–10 years, and 12–14 years (see recommendation
#12).
Recommendation #22 (+)
We recommend screening adults for mental health is-
sues with validated questionnaires that include brief
scales for Anxiety and Depression, such as the NIH
PROMIS Questionnaires, Beck Anxiety Inventory
(BAI), Beck Depression Inventory (BDI) or similar mea-
sures. With adults, we recommend discussing living sit-
uations, work and/or educational situations, satisfaction
with social relationships, and sexual intimacy during out-
patient clinic visits and to refer for professional consul-
tation, if necessary.
Statement #23 (expert opinion, ↓)




Girls with CG should be screened for hypergonadotropic
hypogonadism if they reach the age of 12 years with insuffi-
cient secondary sex characteristics or if they reach the age of
14 years with no regular menses. Screening should include
follicle-stimulating hormone and 17-beta-estradiol.
Recommendation #25 (expert opinion, +)
We recommend to consider follicle stimulating hormone
level, growth, and psychosocial maturity of the individual girl,
for determination of age at start of treatment. For puberty
inducement, a low dose estrogen in a step-wise escalating
dose is used, then later combined with cyclic progesterone
for regular withdrawal bleeds. We recommend considering
referral to a pediatric endocrinologist.
Recommendation #26 (expert opinion, +)
We recommend not using anti-Müllerian hormone and
ovarian imaging routinely for follow-up as these have not
been shown to accurately predict pubertal development or
fertility outcome.
Recommendation #27 (+)
We do not recommend endocrine follow-up for Duarte
Galactosemia, as there is no evidence that the ovaries are
affected.
Recommendation #28 (expert opinion, +)
We recommend that girls and women with CG, who
have gone through puberty and established regular men-
strual periods, should be monitored annually for men-
strual abnormalities, secondary Amenorrhea, and symp-
toms of primary ovarian insufficiency (POI). Changes in
menses or POI symptoms should be evaluated with a
serum follicle-stimulating hormone level. Anti-
Müllerian hormone measurement is not helpful in deter-
mining which women will undergo POI, but may be
helpful in identifying women at risk for imminent POI
when it is undetectable. Imaging by pelvic ultrasound or
MRI is not recommended unless otherwise clinically
indicated.
Recommendation #29 (expert opinion, +)
We recommend that women with hypergonadotropic
hypogonadism, or primary ovarian insufficiency should be
provided counseling and support about their reproductive op-
tions and management of irregular or absent menses.
Hormone replacement therapy should be initiated with the
onset of secondary amenorrhea to reduce the risk of osteopo-
rosis and other complications of primary ovarian
insufficiency.
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Recommendation #30 (++)
We recommend considering a referral to a reproductive
endocrinologist for women who desire pregnancy and have
been unable to conceive naturally, or for women who desire
additional counseling about fertility treatment options includ-
ing oocyte donation.
Recommendation #31 (expert opinion, +)
We recommend providing counseling about adequate birth
control methods for women who do not desire pregnancy.
While combined oral or transdermal contraceptives may pro-
vide cycle control, bone protection, and attenuate hot flashes,
they may fail to provide adequate birth control in women with
very elevated follicle-stimulating hormone levels. An intra-
uterine device may provide the lowest failure rate.
Recommendation #32 (expert opinion, +)
Fertility preservation may not be successful. Currently, fer-
tility preservation techniques are not yet readily used in ev-
eryday practice. We recommend fertility preservation should
only be offered with appropriate institutional research ethics
review board approval to girls with classical galactosemia at a
young pre-pubertal age.
Recommendation #33 (+)




Clinicians should assess bone mineral density (BMD) by
age appropriate dual-energy X-ray absorptiometry (DXA)
scan.
Recommendation #35 (expert opinion, +)(consensus: 93 %)
We recommend BMD screening from age 8–10 years.With
evidence of reduced bone density (Z-score ≤ −2.0), follow-up
according to current pediatric bone health guidelines is
advised.
Without evidence of reduced bone density, we recommend
performing a repeat dual-energy X-ray absorptiometry scan
when puberty is complete. We recommend performing fol-
low-up thereafter every 5 years and treatment instituted ac-
cording to WHO FRAX recommendations.
Recommendation #36 (+)
We recommend comprehensive dietary evaluation, optimi-
zation of calcium intake if needed, monitoring and if neces-
sary supplementation of vitamin D, hormonal status evalua-
tion and hormone replacement therapy consideration, as well
as a regular exercise and assessment of skeletal problems and
clinically significant fractures in all patients with CG.
Supplementation of vitamin K might be beneficial when com-
bined with an adequate intake of calcium and vitamin D, but
currently there is not enough evidence to recommend the rou-
tine use of vitamin K.
Recommendation #37 (expert opinion, +)
At present there is not enough evidence to justify routine
determination of bone turnover markers in patients with CG.
Cataract
Recommendation #38 (++)
Clinicians should refer all patients to an ophthalmologist
for evaluation of cataract at the time of diagnosis.
Recommendation #39 (+)
We recommend performing ophthalmological follow-up in
patients with a cataract at diagnosis until it has fully resolved.
Recommendation #40 (+)
We recommend performing ophthalmological screening in
all patients who are non-compliant with diet.
Closing remarks
The presented guideline is the first international and evidence-
based guideline for the diagnosis, treatment, and follow-up of
CG, and aimed to be applicable worldwide. This guideline
should serve as a guide for clinicians and other experts caring
for patients with CG. Though great effort was undertaken to
formulate evidence-based recommendations, this was frequently
hampered by limited evidence resulting in numerous recommen-
dations based on expert opinion (18/40 recommendations, 45%).
The literature concerning CG available to date mostly consists of
studies with an observational study-design. In the current era of
evidence-based medicine these studies are labeled as having a
low to very low level of evidence. Therefore strength of recom-
mendation is ‘discretionary’ for a majority of recommendations
in the guidelines, (32/40 recommendations, 80 %) including the
recommendations labeled expert opinion. However, as other
study designs (such as RCTs or cohort studies) are usually not
feasible or may not provide the best design to study characteris-
tics of rare diseases, the strength of the recommendation was
upgraded to ‘strong’when results were consistent acrossmultiple
studies, and experts had confidence in the validity of these results
(9/40 recommendations, 23 %).
Future perspectives
Following this conclusion, it is not unexpected that gaps of
knowledge were identified in most discussed fields of interest,
foremost in the fields of treatment and follow-up. Topics of
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major importance for future research include: further assess-
ment of which patients should be treated (cut-off enzyme activ-
ity), exploration for possible further relaxation of the diet for
patients after childhood, exploration of new biomarkers for bio-
chemical follow-up as well as reproductive function, assess-
ment of executive functions in children and adults, and further
exploration of bone turnover markers in relation to BMD.
Guideline update
Revision of this guideline is important as it only represents
evidence in predefined areas up to October 2015. Since re-
search in the field of CG is flourishing, it is expected that new
information will be gained in the next decade. This guideline
is scheduled to be updated in the next 10 years by representa-
tives of the GalNet.
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